ClinicalTrials.gg
Status unknownNCT02899286Updated Jul 28, 2017

Efficacy and Safety Study of Recombinant Human Arginase 1 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

A Phase 2 interventional study of PEG-BCT-100 in Acute Myeloid Leukemia, sponsored by Bio-Cancer Treatment International Limited. Status unknown at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-28.

Sponsored by Bio-Cancer Treatment International Limited · Phase 2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jul 2017), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 25 studies in Leukemia, Myeloid, Acute with a site in Hong Kong — 3 open to participants now, 7 under way, 4 of them phase 3. Leukemia, Myeloid, Acute · Hong Kong.

Planned enrollment
19th of 24
25 · median 70
Started
2016
with 2 others
Phase 2
9 of 25
1 open now
Registered
7th of 25
by date
Lead sponsor
1 of 25
Bio-Cancer Treatment International Limited

Among the 25 studies in Leukemia, Myeloid, Acute with a site in Hong Kong, this one is the 19th largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2016, is one of 9 in phase 2, and was the 7th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

3 of the 25 studies in Leukemia, Myeloid, Acute with a site in Hong Kong are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Hong Kong have not opened yet or have stopped. Only those recruiting at a site in Hong Kong →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Leukemia, Myeloid, Acute with a site in Hong Kong, or all of them as a file.
02

Study summary

To evaluate the efficacy of PEG-BCT-100 in patients with relapsed or refractory acute myeloid leukemia (AML) in terms of remission rate.

Read the detailed description

This is a phase 2, non-randomised, open-label study that aims at evaluating the efficacy of single agent PEG-BCT-100 in adult patients with relapsed/refractory AML. Eligible patients will receive intravenous (IV) infusion of PEG-BCT-100 weekly until disease progression, unacceptable drug-related toxicity(ies), allogeneic haematopoietic stem cell transplantation or withdrawal of subject consent.

Pharmacokinetic (PK) of PEG-BCT-100 and pharmacodynamics (PD) activity of PEG-BCT-100 on arginine depletion will be evaluated throughout the study. Plasma arginine level, intracellular blast arginine level (IBAL) in peripheral blood (PB) and bone marrow (BM) will be measured at specific time points. PEG-BCT-100 will be given once weekly at 1600 Units/kg (2.7mg/kg) per dose for three weeks (Cycle 1). If the post-treatment IBAL-BM examined within 5 days prior to each cycle fails to drop at least 70% from baseline value and disease response fails to achieve complete remission (CR) or complete remission with incomplete blood count recovery (CRi), PEG-BCT-100 may be increased to 2500 U/kg (the maximum tolerated dose as reported previously) at investigator's discretion. Disease response will be assessed within 5 days prior to each cycle according to the International Working Group (IWG) AML Response Criteria.

Safety and toxicity will be assessed through physical examinations, vital signs, blood tests and urinalysis throughout the study. Adverse event (AE) and serious adverse events (SAE) will be reported according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 4.03 (CTCAE v4.03) until 28 days after the last dose of PEG-BCT-100.

Immunogenicity response including anti-drug antibody (ADA) level and neutralizing antibody level will be assessed weekly for the first 2 cycles of PEG-BCT-100, pre-dose of each cycle thereafter and End of Study (EoS). Specific response predictive biomarkers in circulating and BM blasts, and emerging genetic markers will also be explored in the study.

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • Acute myeloid leukemia
  • AML
  • pegylated recombinant human arginase
  • PEG-BCT-100
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients ≥18 year-old at the time of
  2. Documented AML after at least two standard chemotherapy regimen or in whom the treating physicians considered unfit for further chemotherapy treatment
  3. The (ECOG) performance status equal or less than 2
  4. Patients from whom valid consent is obtained

Exclusion criteria

Exclusion Criteria:

  1. Patients who have received any induction chemotherapy, treatment and arginine depleting agent within 2 weeks prior to the start of the PEG-BCT-100 (not including hydroxyurea or thioguanine)
  2. Any toxic effects (except hair loss) of the prior therapy have not been resolved to Grade 1 or less according to National Cancer Institute
  3. Total > 1.5 x (ULN) not related to haemolysis or Gilbert's disease, and ratio of concentrations of and alanine transaminase (AST/ALT) > 5 x ULN
  4. Creatinine > 2 x ULN or estimated using Modification of Diet in Renal Disease formula \< 60 ml/min/1.73 m2
  5. Second active within the past year except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast
  6. Uncontrolled concomitant illness including, but not limited to symptomatic congestive heart failure, unstable angina pectoris or cardiac arrhythmia
  7. History of -1 seropositivity
  8. Active infection not adequately responding to appropriate therapy
  9. Patient is pregnant or lactating
  10. Female with who is not willing to use methods which, in the opinion of the investigator, are effective and adequate while on study treatment and for 6 months after the last dose of study treatment
  11. Male with a female partner with childbearing potential who is not willing to use contraceptive methods which, in the opinion of the investigator, are effective and adequate while on study treatment and for 6 months after the last dose of study treatment
  12. Any condition that is unstable or can jeopardize the safety of the patients and their compliance to the study
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    PEG-BCT-100

    PEG-BCT-100 (PEGylated recombinant human arginase)

    Biological: PEG-BCT-100

Interventions

  • BiologicalPEG-BCT-100

    PEGylated recombinant human arginase

06

What researchers measure

Primary outcomes

  1. Complete remission (CR) rate

    Time frame: 3 years

Secondary outcomes

  1. Overall response rate (ORR)

    proportion of patients achieving CR or CRi or partial remission (PR)

    Time frame: 3 years

  2. Duration of remission

    Time frame: 3 years

  3. Time to progression (TTP)

    Time frame: 3 years

  4. Progression-free survival (PFS)

    Time frame: 3 years

  5. Overall survival (OS)

    Time frame: 3 years

  6. AE and SAE

    Incidence of AE and SAE by severity grading as assessed according to CTCAE v4.03

    Time frame: 3 years

  7. PK - Area under the plasma concentration versus time curve (AUC)

    Time frame: 2 years

  8. PK - Peak plasma concentration of PEG-BCT-100 after administration (Cmax)

    Time frame: 2 years

  9. PK - Lowest concentration that PEG-BCT-100 reaches before the next dose is administered (Cmin)

    Time frame: 2 years

  10. PK - clearance

    Time frame: 2 years

  11. PK - volume of distribution

    Time frame: 2 years

  12. PK - elimination half-life

    Time frame: 2 years

  13. PD

    arginine depletion

    Time frame: 2 years

  14. PK/PD relationship

    dose response

    Time frame: 2 years

  15. Anti-drug antibody (ADA)

    amount of ADA in patient sample (ng/mL)

    Time frame: 2 years

  16. neutralizing anti-drug antibody (nADA)

    amount of nADA in patient sample (ng/mL)

    Time frame: 2 years

07

Study locations

1 site
  • The University of Hong Kong, Queen Mary Hospital
    Hong Kong, Hong Kong
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2016, a primary completion of Sep 2019 and a completion of Mar 2020. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2016
First posted
Sep 14, 2016
Start
Sep 2016
Primary completionEst.
Sep 2019
CompletionEst.
Mar 2020
Last update
Jul 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02899286
Lead sponsor
Bio-Cancer Treatment International Limited
Responsible party
Sponsor
First posted
Sep 14, 2016
Start date
Sep 2016
Primary completion
Sep 2019 (estimated)
Completion
Mar 2020 (estimated)
Last update
Jul 28, 2017

Study contacts

Anskar Leung
principal investigator · The University of Hong Kong

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion